In this session Graham Murray will discuss whether brain structural differences cause mental disorder and whether longitudinal brain changes are a cause for concern or not. Saeed Farooq will present evidence from large prospective studies suggesting that a number of clinical variables can predict lack of response to treatment in first episode psychosis (FEP) along with the findings from an internal validation of a prediction model based on clinical features that are routinely assessed in FEP. He will present an overview of literature on predicting TRS in FEP and the potential use of the prediction model in clinical practice for early detection and management of TRS.
The final talk from James MacCabe will present the key results of the MRC STRATA stratified medicine consortium, a multi-centre programme aiming to develop biomarkers for treatment resistant psychosis. STRATA looks at at genetic and neurochemical differences between people with treatment resistant versus treatment responsive schizophrenia, and the dynamic changes in glutamate in patients starting antipsychotics early in the illness course. Overall the work hopes to identify those who may be at greater risk of non-response to treatment as this may help direct tailored interventions where needed.
After attending this session, you will be able to:
- Understand the clinical relevance of differences in brain imaging findings and their changes over time.
- Understand the clinical predictors of outcome in early psychosis and any potential utility in current practice.
- Understand the current evidence on the predictive capabilities of imaging and genomic biomarkers in relation to psychosis outcomes.
Chair: Fiona Gaughran, National Psychosis Service, South London and Maudsley NHS Foundation Trust, United Kingdom
Graham Murray, University of Cambridge, United Kingdom
Saeed Farooq, Keele University, United Kingdom
James MacCabe, National Psychosis Service, South London and Maudsley NHS Foundation Trust, United Kingdom
